Holly Springs Biomanufacturing Facility
Courtesy of FUJIFILM Biotechnologies
Holly Springs Biomanufacturing Facility
Courtesy of FUJIFILM Biotechnologies
Holly Springs Biomanufacturing Facility
Courtesy of FUJIFILM Biotechnologies
Holly Springs Biomanufacturing Facility
Courtesy of FUJIFILM Biotechnologies
Holly Springs Biomanufacturing Facility
Courtesy of FUJIFILM Biotechnologies
FUJIFILM Biotechnologies opened a $3.2 billion pharmaceutical manufacturing facility in September of 2025 in Holly Springs, N.C. Integrating leading-edge equipment and technologies, the sophisticated development features eight 20,000-liter bioreactors for the production of bulk drug substances and innovative therapies. Johnson & Johnson and Regeneron have signed 10-year contracts to secure space at the 1.3 million-sf campus, which represents the largest end-to-end cell culture CDMO hub in North America.
Created as a near-replica of an existing plant in Denmark, FUJIFILM Biotechnologies' modular approach accelerates design and build timelines, ultimately allowing for faster patient access to biologic medicines and greater supply security. The sustainable complex is powered by clean energy and is on track to attain LEED Gold certification. The transformative project is also slated to achieve a 40 percent reduction in water use, a 75 percent reduction in biohazard waste, as well as landfill diversion rates of 90 percent for operational waste and 85 percent for construction waste. A second phase of development will establish a 425,000-sf facility with eight additional 20,000-liter bioreactors.
